Immunovant Rg
IMVT
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
06/17/2026 - 23:20:00
Bid
06/17/2026 - 21:59:57
Bid
Volume
Ask
06/17/2026 - 21:59:57
Ask
Volume
34.71
+1.10 ( +3.27% )
34.67
200
34.71
1,200
More information
Analysis by TheScreener
16.06.2026
Evaluation Neutral  
Interest Weak  
Sensibility Middle  
Analysis date: 16.06.2026
Global Evaluation
  Neutral
The stock is classified in the neutral zone since 22.05.2026.
Interest
  Weak
Two stars since 16.06.2026.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 16.06.2026 at a price of 33.61.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Positive
 
The dividend-adjusted forty day technical trend is positive since 22.05.2026.
4wk Rel Perf
  20.87%
 
The four-week dividend-adjusted overperformance versus SP500 is 20.87%.
Sensibility
  Middle
The stock has been on the moderate-sensitivity level since 10.04.2026.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -0.34%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 3.34%.
Mkt Cap in $bn
  6.87
With a market capitalization between $2 & $8bn, IMMUNOVANT is considered a mid-cap stock.
G/PE Ratio
  0.23
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
  -20.75
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  4.68%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
  13
Over the last seven weeks, an average of 13 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  151
For 1% of index variation, the stock varies on average by 1.51%.
Correlation
  0.30
Stock movements are strongly independent of index variations.
Value at Risk
  8.07
The value at risk is estimated at USD 8.07. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  01.12.2023